RxDoctor Payments Data

Trisha Field, NP

Family · Beloit, WINPI 1942703285

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 25 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 19.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $456, more than ten times the $38 reported in 2023.

$517in general payments, 2019–2025

Across 25 payments — averaging $20.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$101
  • AstraZeneca$87
  • Astellas Pharma US Inc$65
  • GSK$42
  • Incyte Corporation$39
  • Geron Corporation$34
  • plus $149 from 7 others

What the payments were for

  • Food & beverage$517100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$517 in reported general payments places this provider in the 70th percentile of 1,273 family providers in Wisconsin.

See all family providers in Wisconsin →

Medicare billing

Part B allowed, 2024
$88,384
Medicare patients
106
Services billed
1,025

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl13$16,430
LinzessLinaclotide18$11,116
Breo ElliptaFluticasone/Vilanterol11$4,326
Oxycodone Hcl101$3,384
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen105$3,114
Morphine Sulfate ErMorphine Sulfate52$1,264
Cefaclor20$992
Pregabalin21$620
Buspirone Hcl23$575
Gabapentin46$537
Olanzapine22$457
Pantoprazole Sodium18$348
Potassium Chloride32$312
Tramadol Hcl20$296
Albuterol Sulfate HfaAlbuterol Sulfate19$269

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKBreo Ellipta$42$4,32611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,273 family providers in Wisconsin.

Other family in Beloit

See the full list for Wisconsin →

Where these figures come from

Is this you, or does something look wrong? →